New drug targets Hard-to-Treat heart condition
NCT ID NCT07103655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called mavacamten in 132 people with hypertrophic cardiomyopathy (thick heart muscle) that blocks blood flow in the middle or tip of the heart's main pumping chamber. The goal is to see if mavacamten can reduce the pressure difference across the blockage and improve heart function. Participants will take mavacamten along with standard treatments like beta-blockers or diltiazem.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mavacamten
What this could lead to
If it works, this could provide a new treatment option for a specific type of hypertrophic cardiomyopathy that is hard to treat.
What could go wrong
This is a small, early-phase study (phase 4) with only 132 participants. It may not show clear benefits, and mavacamten can have side effects like heart failure or arrhythmias.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••